NSE - Delayed Quote INR

Medicamen Biotech Limited (MEDICAMEQ.NS)

Compare
476.10
-20.75
(-4.18%)
At close: January 10 at 3:29:05 PM GMT+5:30
Loading Chart for MEDICAMEQ.NS
DELL
  • Previous Close 496.85
  • Open 496.10
  • Bid --
  • Ask --
  • Day's Range 476.00 - 501.85
  • 52 Week Range 355.45 - 630.00
  • Volume 18,677
  • Avg. Volume 66,108
  • Market Cap (intraday) 6.065B
  • Beta (5Y Monthly) 1.50
  • PE Ratio (TTM) 82.94
  • EPS (TTM) 5.74
  • Earnings Date Feb 10, 2025 - Feb 14, 2025
  • Forward Dividend & Yield 1.00 (0.22%)
  • Ex-Dividend Date Sep 19, 2024
  • 1y Target Est --

Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarial, vitamins and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.

www.medicamen.com

378

Full Time Employees

March 31

Fiscal Year Ends

Recent News: MEDICAMEQ.NS

View More

Performance Overview: MEDICAMEQ.NS

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

MEDICAMEQ.NS
4.96%
S&P BSE SENSEX
1.11%

1-Year Return

MEDICAMEQ.NS
16.04%
S&P BSE SENSEX
8.39%

3-Year Return

MEDICAMEQ.NS
49.20%
S&P BSE SENSEX
29.52%

5-Year Return

MEDICAMEQ.NS
13.77%
S&P BSE SENSEX
86.67%

Compare To: MEDICAMEQ.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MEDICAMEQ.NS

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    6.10B

  • Enterprise Value

    6.24B

  • Trailing P/E

    83.47

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.35

  • Price/Book (mrq)

    2.82

  • Enterprise Value/Revenue

    3.43

  • Enterprise Value/EBITDA

    28.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.49%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.8B

  • Net Income Avi to Common (ttm)

    81.05M

  • Diluted EPS (ttm)

    5.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    147.86M

  • Total Debt/Equity (mrq)

    15.37%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: MEDICAMEQ.NS

View More

People Also Watch